Supplement Industry Lobbies FDA to Permit Peptides and Novel Ingredients
Dietary supplement manufacturers are intensifying efforts to persuade the Food and Drug Administration to expand the permissible ingredients in their products. This potential regulatory shift could facilitate the marketing of peptides, probiotics, and other contemporary wellness offerings that currently fall outside traditional definitions.
FDA Holds Crucial Public Meeting on Ingredient Criteria
The FDA convened a public meeting on Friday to re-evaluate its long-standing criteria for dietary supplements. The discussion centered on whether these criteria should be broadened to include substances not derived from conventional sources like food, vitamins, or herbs. Agency officials gathered insights from industry executives, consumer advocates, and academic experts during the session.
This marks the first such meeting since Robert F. Kennedy Jr. assumed the role of the nation's top health official last year. Kennedy has publicly committed to ending what he terms the "war at FDA" on dietary supplements, peptides, and related products, aligning with his Make America Healthy Again movement's priorities.
Industry Pressure and Regulatory Ambiguity
Friday's meeting was initiated at the request of the Natural Products Association, an industry group that has previously clashed with the FDA over new supplement ingredients. In a January letter, the association highlighted "the cost and uncertainty that arise when regulatory expectations are unclear," urging the agency to clarify its stance.
Under current FDA regulations, supplements are classified as a category of food, with most ingredients expected to originate from plants, herbs, or other dietary substances. This requirement has become increasingly problematic as newer wellness products incorporate ingredients never historically used in food.
Peptides, for example, are drug-like chains of amino acids promoted by celebrities and influencers for muscle building and anti-aging benefits, despite limited scientific backing. While often sold as injections or IV infusions by specialty pharmacies, some supplement makers are now adding them to capsules, gummies, and powders—a practice that FDA lawyers argue technically violates existing rules.
Similarly, certain probiotics—bacteria-containing products marketed for digestive and gut health—also face regulatory hurdles. Companies contend that FDA law does not explicitly mandate all ingredients must be food-derived, advocating for a more flexible interpretation.
Robert Durkin, a former FDA supplements program official now consulting for companies, stated, "The hope of the meeting is that FDA is willing to open up its interpretation of what constitutes a dietary ingredient to allow dietary substances that aren't already in food." If the agency resists redefining the term, the industry may pursue legal action, leveraging a 2024 Supreme Court decision that curtailed federal regulators' authority to interpret laws unilaterally.
Kennedy's Influence and Industry Connections
Kennedy has emerged as a perceived ally for supplement makers, recently declaring himself "a big fan" of peptides and sharing personal usage experiences on Joe Rogan's podcast. He has pledged to relax FDA restrictions on injectable peptides, which are currently subject to federal safety limits.
Allies and supporters of Kennedy, including Gary Brecka, a self-described "longevity expert" selling peptide products online, and Dr. Mark Hyman, who markets supplements claiming peptide content, bolster this pro-industry stance. Additionally, two former health advisers from Kennedy's presidential campaign have ties to the sector.
Calley Means, now a senior adviser at the Department of Health and Human Services, co-founded a platform facilitating tax-free health spending on supplements. His sister, Dr. Casey Means—formerly nominated as surgeon general by President Donald Trump—earned significant income promoting supplements and probiotics, as per financial disclosures.
Lax Oversight and Marketing Claims
The FDA does not pre-approve dietary supplements for safety or efficacy, unlike drugs and medical devices. With an estimated 100,000 or more products on the market, manufacturers bear legal responsibility for safety and truthful advertising, though supplements cannot claim to treat specific diseases.
The 1994 law governing FDA oversight exempted supplement makers from rigorous nutrition labeling requirements, allowing more general health claims without scientific substantiation. Former regulator Mitch Zeller criticized this approach, noting it "sanctioned unauthorized, implied health claims" and enabled carefully worded marketing that avoids explicit treatment assertions.
Companies may assert products improve body structure or function, such as bone strengthening, provided they include the disclaimer: "This statement has not been evaluated by the FDA." This regulatory gap continues to fuel debate over consumer protection and industry innovation.
